Alongside Skyclarys, Biogen’s rare disease business is headed by spinal muscular atrophy treatment Spinraza (nusinersen). Spinraza generated global Q1 2025 sales of $423.9m, up from $341.3m in ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

Biogen Q1 EPS hit $3.02 vs. $2.52 estimate; revenue rose 6% to $2.43 billion, beating the $2.23 billion consensus. Rare disease sales rose 33% to $563 million; Spinraza revenue climbed to $423.9 ...

Biogen said about 75% of its U.S. revenue last year came from products manufactured in the country, which includes Leqembi and spinal muscular atrophy treatment Spinraza. Biogen expects 2025 ...

Zolgensma costs around $2.125 million, which works out at $425,000 per year over five years, around half the cost of ten years’ treatment with Spinraza. Image Richard Staines ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with ...

At this time, I'd like to welcome everyone to the Biogen First Quarter 2025 Earnings ... And actually in line pretty much with the SPINRAZA launch, I wasn't here for that, but as we've gone ...